SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-007032
Filing Date
2020-02-27
Accepted
2020-02-27 07:49:23
Documents
17
Period of Report
2020-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K Q419 EARNINGS RELEASE ntla-8k_20200227.htm   iXBRL 8-K 41081
2 EX-99.1 ntla-ex991_19.htm EX-99.1 68866
3 GRAPHIC griq43ptuuvw000008.jpg GRAPHIC 36180
4 GRAPHIC griq43ptuuvw000001.jpg GRAPHIC 19091
5 GRAPHIC griq43ptuuvw000002.jpg GRAPHIC 1900
6 GRAPHIC griq43ptuuvw000009.jpg GRAPHIC 18025
  Complete submission text file 0001564590-20-007032.txt   355777

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA ntla-20200227.xsd EX-101.SCH 5960
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20200227_lab.xml EX-101.LAB 19475
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20200227_pre.xml EX-101.PRE 11626
17 EXTRACTED XBRL INSTANCE DOCUMENT ntla-8k_20200227_htm.xml XML 3550
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 20658513
SIC: 2835 In Vitro & In Vivo Diagnostic Substances